Ovarian Cancer Clinical Trials

Showing 221-240 of 1,019 trials

CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer

NCT05942300

This is a clinical trial using CPI-0209 in combination with Carboplatin chemotherapy followed by CPI-0209 maintenance in patients with platinum sensitive, recurrent ovarian cancer.

Recurrent Ovarian Cancer

Lan Coffman30 participantsStarted Jan 2024

Pittsburgh, Pennsylvania, United States

RECRUITINGNA

ASk Questions in GYnecologic Oncology (ASQ-GYO)

NCT06339827

The goal of this clinical trial is to determine the effectiveness of the ASk Questions in GYnecologic Oncology question prompt list (ASQ-GYO QPL) at improving patient self-efficacy, distress, physician trust, and knowledge compared to usual care during new patient gynecologic oncology visits. Also to determine the acceptability of the ASQ-GYO QPL with new gynecologic oncology patients.

Ovarian CancerEndometrial CancerCervical Cancer+3 more

Ira Winer70 participantsStarted Apr 2024

Detroit, Michigan, United States

RECRUITINGPhase 2

RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer

NCT03675893

This research study is studying a combination of targeted therapies as a possible treatment for estrogen-receptor positive (ER+) endometrial cancer and low-grade serous ovarian cancer. The drugs involved in this study are: * Abemaciclib (also known as Verzenio™) * Letrozole (also known as Femara®) * Metformin (also known as Glucophage®) * Zotatifin (also known as eFT226) * Gedatolisib (also known as PF-05212384)

Endometrial CancerOvarian Cancer

Dana-Farber Cancer Institute180 participantsStarted Dec 2018

Boston, Massachusetts, United States • Boston, Massachusetts, United States • Boston, Massachusetts, United States

CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer

ASk Questions in GYnecologic Oncology (ASQ-GYO)

RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer

Related Searches

European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer

Expanded Access of Vigil in Solid Tumors

A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer

Genetic Risk Assessment for Cancer Education and Empowerment (GRACE) Project

Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors

Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer

EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer

Phase II Study of Utidelone Plus Fruquintinib Combination Therapy for Platinum-Resistant Recurrent Ovarian Cancer

Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy

Tempus Priority Study: A Pan-tumor Observational Study

A Study of LY2880070 in Participants With Advanced or Metastatic Cancer

IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer

IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer